DecisionBase 2009 Now Available from Decision Resources
Posted on: Thursday, 2 April 2009, 07:00 CDT
Assesses Opportunity and Unmet Need in Thirty-Five Indications
Expanded Primary Research Includes European Physicians
"In response to these changing times, we have revamped our data and analysis tool DecisionBase to better address the needs of the drug industry," stated
The new tool DecisionBase 2009 provides detailed market share, patient share and price-per-day projections for key current and emerging drugs in 35 indications across the G7 pharmaceutical markets (U.S.,
"In the commercial environment we examine pricing, reimbursement, regulatory issues and drug labeling," added Dr. Drayton. "In the clinical environment, we evaluate clinical differentiators of key current and emerging therapies, factors that influence prescribing decisions and drug choice, patient population, country-specific medical practice and current therapies' impact on quality of life measures."
Indications covered in DecisionBase 2009 include:
Cardiovascular
- Acute Heart Failure
- Atrial Fibrillation
- Coronary Heart Disease (Stable Angina)
- NSTEMI (Non-ST-Elevated Myocardial
- Infarction)
- STEMI (ST-Elevated Myocardial
- Infarction)
- Venous Thromboembolism
CNS
- Alzheimer's Disease (Mild-to-Moderate)
- Attention-Deficit/Hyperactivity Disorder
- Bipolar Depression
- Cognitive Impairment Associated with
- Schizophrenia
- Epilepsy
- Multiple Sclerosis (Relapsing-Remitting)
- Parkinson's Disease
High Profile Diseases
- Erectile Dysfunction
Infectious Diseases
- Hepatitis C
- HIV
- Hospital-Acquired Pneumonia
Immune & Inflammatory Diseases
- Asthma
- Atopic Dermatitis
- Chronic Obstructive Pulmonary Disease
- Crohn's Disease
- Psoriasis
- Rheumatoid Arthritis
- Ulcerative Colitis
Metabolic
- Type 1 Diabetes
- Type 2 Diabetes
Oncology
- Breast Cancer (HER2-Positive)
- Breast Cancer (Metastatic Triple Negative)
- Glioma (High Grade)
- Malignant Melanoma (Stage IV)
- Chronic Lymphocytic Leukemia (Relapsed/Refractory)
- Prostate Cancer (Metastatic, Hormone Refractory)
- Prostate Cancer (Stage III)
- Renal Cell Carcinoma (Metastatic)
Pain
- Chronic Low Back Pain
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Congressman Mike Thompson (D-CA) Adds His Name As Co-Sponsor to the Lung Cancer Mortality Reduction Act of 2009
- Infragistics Announces NetAdvantage for Silverlight Data Visualization 2009 Volume 2
- Survey: Men Not Adequately Involved In Decisions About Prostate Cancer Screening
- Pyramid Research Launches Web-Based Data Tool, Unlocking More Value from Industry-Leading Forecasts
- Zepol Corporation Announces TradeView(TM), a New U.S. Census Merchandise Trade Data Tool
- Biotech Hot in July Driven by Positive Drug Data and Acquisitions
- BDSI Presents Significant Cancer Pain Drug Data
- Study Examines Side Effects of Breast Cancer Prevention Drugs
- Cancer Researcher Admits to Faking Data
- Researchers Tested AIDS Drugs on Children
 |
 |
User Comments (0)
RSS Feeds